syncytial


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to syncytial: respiratory syncytial virus

syn·cy·ti·um

 (sĭn-sĭsh′ē-əm)
n. pl. syn·cy·ti·a (-sĭsh′ē-ə)
A multinucleated mass of cytoplasm that is not separated into individual cells.

[New Latin : syn- + cyt(o)- + -ium.]

syn·cy′ti·al (-sĭsh′ē-əl) adj.
Translations

syn·cy·tial

a. sincitial, rel. a un sincitio o que lo constituye.
References in periodicals archive ?
M2 PHARMA-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults
M2 EQUITYBITES-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
Global Banking News-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
Summary: Respiratory syncytial virus infection is highly contagious.
Respiratory syncytial virus (RSV) is a Pneumovirus that belongs to the Pneumovirinae subfamily of the Paramyxoviridae family.
Keywords: Abruptio placenta, APH (antepartum hemorrhage), Calcification, Cotyledon, Diameter in centimeters, Fibrinoid necrosis, Syncytial knots, Weight in grams.
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children worldwide (1-3); 2.7-3.8 million hospitalizations and 94,600-149,400 deaths occur each year among children <5 years of age as a result of RSV infection (4).
Respiratory syncytial virus (RSV)-positive laboratory detections have been reportable in Arizona since 2004 as part of the state's passive infectious disease surveillance.
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency has granted access to its PRIME, or PRIority MEdicines, scheme for MEDI8897, an extended half-life respiratory syncytial virus F monoclonal antibody being developed for the prevention of lower respiratory tract infection caused by RSV.